Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused
Plus: Hyperimmune Globulin Trial Launched
• By Scrip Team
The ACTIV-3 Trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
